^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Angiogenesis inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China

    Published date:
    05/24/2022
    Excerpt:
    A total of 164 patients were screened, identifying 35 kinds of ex20ins, and 122 cases treated with C, C + I, and C + A were finally included in the first-line analysis. C + A achieved much better objective response rate (ORR, 38.1% vs. 18.2%) and significant progression-free survival (PFS) benefit compared with C (median, 7.73 vs.5.93 months, HR = 0.60, 95% CI: 0.40–0.90, p = 0.014)...
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1002/cam4.4852